NHS England announces annual investment decisions for certain specialised services

Following a three-month public consultation on the principles and processes they will follow when making investment decisions,  NHS England has set out its planned investment decisions for certain specialised services as part of its annual commissioning round. 39 proposed new investments have been carefully considered.

The following services and treatments will be routinely commissioned:

  • Duodopa as a treatment to control the symptoms of patients with advanced Parkinson’s Disease
  • A programme of BRCA1/2 gene testing, helping women to discover if they have harmful genetic mutations which can increase the likelihood of developing breast or ovarian cancer
  • A raft of new genetic tests to be provided by the UK Genetic Test Network
  • Widening access to Proton Beam Therapy for certain types of cancer, for both children and adults
  • New treatments – bedaquiline and delamanid – for drug-resistant tuberculosis
  • Robotic-assisted surgery for early stage prostate cancer
  • Cervical disc replacement to address spinal degeneration
  • Extending treatment with Ivacaftor for Cystic Fibrosis with the G551D mutation
  • Riociguat for use in chronic thromboembolic pulmonary hypertension
  • Sildenafil and Bosentan for digital ulceration in systemic sclerosis
  • Intrathecal drug delivery for cancer pain
  • Occipital nerve stimulation for intractable headaches & migraine
  • Rituximab for steroid sensitive nephrotic syndrome in children
  • Rituximab for steroid resistant nephrotic syndrome in children
  • Rituximab for acquired haemophilia
  • Biologics for Juvenile Idiophatic Arthritis in children and adults
  • Sacral nerve stimulation for urinary incontinence and retention
  • Management of fetal anaemia secondary to red cell alloimmunisation (Fetal transfusion)
  • A new service for hand transplants, giving those with amputated forearms an alternative to prosthetics
  • New guidelines on the use of Positron emission tomography–computed tomography (PET-CT)
  • Elvitegravir/cobicistat/emtricitabine/tenofovir for treatment of human immunodeficiency virus (HIV) Type 1 infection in adults
  • Cobicistat for booster in treatment of HIV positive adults and adolescents
  • A Treatment as Prevention programme for patients with HIV, to both reduce mortality and illness for the patients themselves and the risk of transmission by reducing viral load

The following treatments and services will not be routinely commissioned:

  • Two separate policies on Deep Brain Stimulation for chronic pain and refractory epilepsy
  • Three separate policies on new types of prosthetic limbs
  • The use of Sapropterin to treat the rare genetic condition Phenylketonuria (PKU) in children.
  • Eculizumab and Bortezomib for prevention of organ rejection post kidney transplantation
  • Cytoreductive surgery with HIPEC for peritoneal mesothelioma
  • Intrathecal Drug Delivery for chronic non-cancer pain
  • Infliximab (Remicade) and Adalimumab (Humira) Anti-TNF treatment options for adults and children with severe refractory uveitis

Further information can be found here. 


Published 2. July 2015 in News UK